Ticker: CLRB

Cellectar Biosciences, Inc. (NASDAQ: CLRB) Quick take: management is cutting spending after finishing enrollment in its pivotal CLOVER WaM study, has FDA Breakthrough Therapy designation for iopofosine I‑131, but remains capital‑constrained with a formal going‑concern warning and material weaknes...

Cellectar Biosciences, Inc. (NASDAQ: CLRB) has recently released its quarterly earnings report for the period ending March 31, 2025. The company is focused on the research and development of cancer therapies utilizing its proprietary Phospholipid Drug Conjugate (PDC) platform. Key Financial Highl...